Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression

Paclitaxel is a first-line drug for treating epithelial ovarian cancer (EOC). However, prognosis for patients with advanced stage cancer remains poor due to primary or acquired drug resistance. Therefore, overcoming chemoresistance is one of the greatest challenges in treating EOC. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Koji, Sawada, Kenjiro, Miyamoto, Mayuko, Kinose, Yasuto, Yoshimura, Akihiko, Ishida, Kyoso, Kobayashi, Masaki, Shimizu, Aasa, Nakatsuka, Erika, Hashimoto, Kae, Mabuchi, Seiji, Kimura, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363016/
https://www.ncbi.nlm.nih.gov/pubmed/30774764
http://dx.doi.org/10.18632/oncotarget.26586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363016/
https://www.ncbi.nlm.nih.gov/pubmed/30774764
http://dx.doi.org/10.18632/oncotarget.26586

Ejemplares similares